Dublin, Jan. 27, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/gh87ph/pediatric_drugs) has announced the addition of the "Pediatric Drugs and Vaccines - Global Strategic Business Report" report to their offering.
This report analyzes the worldwide markets for Pediatric Drugs and Vaccines in US$ Million by the following Therapeutic Class: Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs, and Other Pediatric Drugs. The market for 'Pediatric Vaccines' in this report is analyzed by the following Type: Combinations, Hepatitis, MMR, Varicella, Poliovirus, Pneumococcal, and Others.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 120 companies including many key and niche players.
Key Topics Covered:
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
2. MARKET TRENDS AND ISSUES
3. REGULATORY ENVIRONMENT
4. PEDIATRIC VACCINES MARKET
5. PEDIATRIC DISEASES - OVERVIEW, STATISTICS & TREATMENT
6. LIST OF SELECT FDA APPROVED PEDIATRIC DRUGS
7. PRODUCT INTRODUCTIONS/INNOVATIONS
8. RECENT INDUSTRY ACTIVITY
9. FOCUS ON SELECT GLOBAL PLAYERS
- Actelion Pharmaceuticals Ltd (Switzerland)
- Abbott Laboratories (US)
- Allergan, Inc. (US)
- Amgen, Inc. (US)
- AstraZeneca Plc. (UK)
- Boehringer Ingelheim GmbH (Germany)
- Bristol-Myers Squibb Company (US)
- Crucell N.V. (The Netherlands)
- Eli Lilly and Company (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Genentech, Inc. (US)
- GlaxoSmithKline plc. (UK)
- InfaCare, Inc. (USA)
- Merck & Co., Inc. (US)
- Merck Serono (Switzerland)
- Novartis AG (Switzerland)
- Novo Nordisk A/S (Denmark)
- Pfizer, Inc. (US)
- Sanofi S.A (formerly Sanofi-Aventis) (France)
- Shionogi Inc. (US)
- Shire Pharmaceuticals Group Plc (UK)
10. GLOBAL MARKET PERSPECTIVE
III. MARKET
1. THE UNITED STATES
2. CANADA
3. JAPAN
4. EUROPE
5. ASIA-PACIFIC
6. LATIN AMERICA
7. REST OF WORLD
8. APPENDIX 1: LIST OF ALREADY APPROVED FDA DRUM8GS FOR WHICH LABELING CHANGES WERE MADE TO INCLUDE PEDIATRIC INDICATIONS
9. APPENDIX 2: LIST OF DRUGS OBTAINING PEDIATRIC EXCLUSIVITY BY FDA
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 120 (including Divisions/Subsidiaries - 131)
- The United States (78)
- Canada (4)
- Japan (5)
- Europe (35)
- France (4)
- Germany (4)
- The United Kingdom (5)
- Rest of Europe (22)
- Asia-Pacific (Excluding Japan) (8)
- Latin America (1)
Companies Mentioned:
- Actelion Pharmaceuticals Ltd.
- Abbott Laboratories
- Allergan, Inc.
- Amgen, Inc.
- AstraZeneca Plc
For more information visit http://www.researchandmarkets.com/research/gh87ph/pediatric_drugs